Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meplazumab in Severe COVID-19
NCT05679479Phase 3Completed
- Sponsor
- Jiangsu Pacific Meinuoke Bio Pharmaceutical Co., Ltd.
- Start
- Jan 2024
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of meplazumab in coronavirus disease 2019 (COVID-19), sponsored by Jiangsu Pacific Meinuoke Bio Pharmaceutical Co., Ltd.. Started Jan 2024; status: completed.
02
Drugs
meplazumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05679479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05679479.